

Cyient DLM

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	CYIENTDL IN
Equity Shares (m)	79
M.Cap.(INRb)/(USDb)	49.5 / 0.5
52-Week Range (INR)	628 / 265
1, 6, 12 Rel. Per (%)	31/76/35
12M Avg Val (INR M)	213

Financials & Valuations (INR b)

Y/E Mar	FY26	FY27E	FY28E
Sales	12.6	16.4	20.5
EBITDA	1.3	1.9	2.6
Adj. PAT	0.6	1.1	1.6
EBITDA Margin (%)	10.3	11.5	12.5
Cons. Adj. EPS (INR)	7.2	13.5	20.1
EPS Gr. (%)	-22.7	87.2	48.9
BV/Sh. (INR)	127.6	141.1	161.2

Ratios

Net D:E	-0.0	-0.3	-0.3
RoE (%)	5.8	10.0	13.3
RoCE (%)	7.1	10.6	14.0

Valuations

P/E (x)	86	46	31
EV/EBITDA (x)	38	24	18

Shareholding pattern (%)

As on	Mar-26	Dec-25	Mar-25
Promoter	52.1	52.1	52.2
DII	26.7	28.8	28.7
FII	0.8	0.5	2.4
Others	20.4	18.6	16.8

Note: FII includes depository receipts

CMP: INR623

TP: INR800 (+28%)

Buy

Growth momentum returns

Operating performance beats estimates

- Cyient DLM's (CYIENTDL) 1QFY27 consolidated revenue/EBITDA grew 34%/56% YoY to INR3.7b/INR392m, largely aided by 41%/95% YoY growth in aerospace/industrial segments. EBITDA margins expanded by 150bp YoY to 10.5%, led by operating leverage.
- We believe FY27 could mark an inflection year for CYIENTDL owing to order book growth of 22% YoY to INR26b, the ramp-up of aerospace programs (Honeywell and Thales), increasing B2S/box-build contribution, and benefits of operating leverage. These factors should lead to stronger revenue growth and margin expansion. Its expansion into AI data center infrastructure, robotics and semiconductor equipment creates additional growth avenues, strengthening the company's growth visibility.
- Factoring in the strong 1Q performance, we raise our earnings estimates by 5%/7% for FY27E/FY28E and estimate a CAGR of 27%/40%/67% in revenue/EBITDA/ adj. PAT over FY26-28E. We reiterate our BUY rating on the stock with a **TP of INR800** (40x FY28E EPS).

Robust growth accompanied by improving margins

- Consol. revenue grew 34% YoY to INR3.7b (est. INR3.5b). Revenue from Aerospace/Defense/Industrial grew 41%/34%/95% YoY, while revenue from Medtech/Auto & others declined 7%/78% YoY.
- The company's order backlog expanded 22% YoY to INR26b, driven by a strong order intake of ~INR5.6b in 1QFY27 (vs. avg. order intake of INR4.3b in the last eight quarters).
- Though gross margin contracted 230bp to 37.9% due to a change in the product mix, EBITDA margins expanded 150bp YoY to 10.5% (est. 9.6%), driven by better operating leverage. EBITDA grew 56% YoY to INR392m (est. INR338m). Adj. PAT was up 2.2x YoY at INR163m (est. in line).
- NWC as of Jun'26 improved by 4 days YoY to 161 days, led by a reduction in inventory days to 162 (vs. 185 in 1QFY26).

Highlights from the management commentary

- **New verticals:** The company is expanding into AI data center infrastructure, robotics and semiconductor capital equipment to drive the next phase of growth. Management expects initial order wins during FY27, with revenue contribution scaling up over time. The company is already seeing traction in semiconductor equipment and can pursue these opportunities by largely using the existing manufacturing infrastructure, limiting incremental capex requirements.
- **Aerospace:** Management highlighting strong positioning across leading global aerospace OEMs and Tier-1 suppliers, including most major European aerospace players. Previously secured programs like Honeywell are expected to ramp up significantly over the next 12-18 months, while Thales is also expected to contribute meaningfully to growth in FY27. Aerospace is characterized by stringent qualification requirements and long approval cycles, creating high entry barriers and highly sticky, long-

Research Analyst: Sumant Kumar (Sumant.Kumar@MotilalOswal.com) | **Swapnil Upadhyay** (Swapnil.Upadhyayk@MotilalOswal.com)

Research Analyst: Nirvik Saini (Nirvik.saini@MotilalOswal.com) | **Yash Darak** (Yash.Darak@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

duration revenue streams once a supplier is onboarded. Additionally, the company is undertaking engineering and design work for SkyDrive's eVTOL platform (B2S), with production expected to commence in the next 18-24 months.

- **Margin expansion:** Management expects margins to improve to 11-13% over FY27-29 through increasing contributions from AI infrastructure, robotics and semiconductor equipment. Higher B2S and platform-led revenue could drive long-term EBITDA margins toward 13-18%, with B2S alone expected to add 250-300bp to consolidated margins over time.

Valuation and view

- CYIENTDL started FY27 on a strong note with a healthy order book, reinforcing confidence in its growth trajectory. We believe the company is entering a multi-year growth phase, supported by a) a ramp-up in aerospace programs (like Honeywell and Thales), b) increasing contributions from higher-margin box-build and B2S offerings, and c) expansion into AI infrastructure, robotics and semiconductor equipment.
- We expect FY27 to mark the beginning of an accelerated earnings growth cycle, supported by operating leverage, an improving product mix and rising contributions from high-value engineering-led programs.
- We estimate a CAGR of 27%/40%/67% in revenue/EBITDA/adj. PAT over FY26-28E. We reiterate our BUY rating on the stock with a **TP of INR800** (40x FY28E EPS).


Consolidated - Quarterly Earnings

(INR m)

Y/E March	FY26				FY27				FY26	FY27E	FY27E	Var
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			1QE	%
Gross Sales	2,784	3,106	3,033	3,691	3,738	3,852	3,979	4,830	12,615	16,399	3,508	7
YoY Change (%)	8.0	-20.2	-31.7	-13.8	34.3	24.0	31.2	30.9	-17.0	30.0	26.0	
Total Expenditure	2,534	2,794	2,724	3,260	3,346	3,401	3,534	4,231	11,312	14,513	3,171	
EBITDA	251	312	309	431	392	451	444	599	1,302	1,886	338	16
Margins (%)	9.0	10.0	10.2	11.7	10.5	11.7	11.2	12.4	10.3	11.5	9.6	
Depreciation	105	106	108	109	111	112	116	118	428	457	110	
Interest	86	68	61	56	61	52	45	42	272	200	54	
Other Income	42	31	43	51	3	63	65	70	167	200	45	
PBT before EO expense	101	169	183	317	222	350	348	509	770	1,429	219	
Extra-Ord expense	0	-196	34	0	0	0	0	0	-162	0	0	
PBT	101	365	149	317	222	350	348	509	932	1,429	219	
Tax	26	43	37	92	59	87	87	127	199	360	55	
Rate (%)	26.1	11.9	24.6	29.2	26.7	24.9	24.9	24.9	21.3	25.2	25.2	
Reported PAT	75	321	112	224	163	263	262	382	733	1,069	164	
Adj PAT	75	126	147	224	163	263	262	382	571	1,069	164	0
YoY Change (%)	-29.6	-18.7	-13.0	-27.7	118.2	108.9	78.7	70.2	-22.7	87.2	60.2	
Margins (%)	2.7	4.0	4.8	6.1	4.4	6.8	6.6	7.9	4.5	6.5	4.7	


Key exhibits

Exhibit 1: Consolidated order book trend




Source: Company, MOFSL

Exhibit 2: Consolidated revenue trend




Source: Company, MOFSL

Exhibit 3: Consolidated EBITDA trend




Source: Company, MOFSL

Exhibit 4: Consolidated adj. PAT trend




Source: Company, MOFSL

Exhibit 5: Product-wise revenue mix



Source: Company, MOFSL

Exhibit 6: End-user industry-wise revenue mix



Source: Company, MOFSL



Highlights from the management commentary

Order book remains at record high; visibility strengthens

- CYIENTDL closed 1QFY27 with its highest-ever order book of INR26b, providing strong revenue visibility for the coming quarters.
- The company reported order intake of INR5.52b during the quarter, translating into a healthy book-to-bill ratio of 1.5x.
- Management indicated that order inflows were broad-based without any large one-off orders and were driven by both existing and newly acquired customers.
- Around 70% of quarterly order intake came from existing customers, while the balance 30% was contributed by customers added over the last four quarters.
- The sales pipeline remains robust, with management indicating a substantially larger opportunity pool than currently reflected in the order book.

Expansion into AI infrastructure, robotics and semiconductor equipment

- Cyient DLM has formally identified AI infrastructure, data centers and robotics as its next growth vectors under the FY27-FY29 expansion phase.
- Dedicated leadership resources have been onboarded to drive customer acquisition and market development in these emerging segments.
- Management expects order wins from these sectors to start materializing during FY27, while meaningful revenue contribution could emerge over the medium term.
- The company is already engaged with customers in semiconductor capital equipment and expects stronger revenue traction from this segment over the next 6-12 months.
- Existing manufacturing infrastructure is largely sufficient to address these opportunities, limiting the requirement for incremental capex.

Aerospace continues to anchor growth

- Aerospace remained the largest business segment, contributing 42% of revenue and delivering 40% YoY growth.
- Management highlighted strong positioning with leading global aerospace OEMs and Tier-1 suppliers, creating a significant competitive moat.
- Several previously awarded aerospace programs, particularly with Honeywell, are expected to ramp up over the next 12-18 months.
- The company also expects healthy growth from key customers such as Thales and other global aerospace players.
- Management reiterated that aerospace offers long-term revenue stability owing to high entry barriers, lengthy qualification cycles and strong customer stickiness.

Margin expansion strategy remains intact

- EBITDA margin improved 147bp YoY to 10.5%, marking the fourth consecutive quarter of double-digit EBITDA margins.
- Near-term margin expansion continues to be driven by operating leverage, better revenue mix and disciplined cost management.
- Management expects EBITDA margins to improve toward 11-13% during the FY27-FY29 expansion phase through increasing exposure to AI infrastructure, robotics and semiconductor equipment.

- Over the longer term, higher contribution from build-to-specification (B2S) products and platform-led offerings is expected to drive margins toward the 13-18% range.
- B2S products are expected to contribute an additional 250-300bp of consolidated EBITDA margin improvement over time.

Working capital elevated amid growth investments

- Inventory days increased to 162 as the company continued strategic inventory stocking to mitigate supply-chain disruptions and support future growth.
- Net working capital increased to 161 days, driven by higher inventory and lower customer advances.
- Management emphasized that inventory investments remain a deliberate strategy to ensure uninterrupted execution amid geopolitical uncertainties.
- Free cash flow remained impacted by working capital investments, though management expects normalization as inventory levels stabilize.

West Asia challenges managed through proactive planning

- The West Asia crisis continues to cause logistics delays and high freight costs across supply chains.
- Management stated that proactive procurement planning, inventory stocking and alternate sourcing initiatives have successfully prevented any operational disruptions.
- Similar mitigation measures have already been implemented for 2QFY27.
- Importantly, order momentum from Israeli customers remains healthy, with management expecting continued traction in the coming quarters.

Other

- MedTech growth remained muted due to seasonality at one customer, though management sees no structural weakness and maintains a healthy opportunity pipeline.
- The company expanded its B2S lab capacity from 6,000 sqft to 15,000 sqft and completed the NADCAP certification audit for cable harness assembly at its Mysore facility.
- Management remains confident of sustaining current growth momentum and maintaining a book-to-bill ratio of around 1.5x through FY27.

Valuation and view

- CYIENTDL delivered a strong start to FY27 and a healthy order book, reinforcing confidence in its growth trajectory. We believe the company is entering a multi-year growth phase supported by a) ramp-up in aerospace programs (like Honeywell and Thales), b) increasing contributions from higher-margin box-build and B2S offerings, and c) expansion into AI infrastructure, robotics and semiconductor equipment.
- We expect FY27 to mark the beginning of an accelerated earnings growth cycle, supported by operating leverage, improving product mix and rising contribution from high-value engineering-led programs.
- We estimate a CAGR of 27%/40%/67% in revenue/EBITDA/ adj. PAT over FY26-28E. We reiterate our BUY rating on the stock with a **TP of INR800** (40x FY28E EPS).

Exhibit 7: Revised estimates

Earnings change (INR m)	Old		New		Change	
	FY27E	FY28E	FY27E	FY28E	FY27E	FY28E
Revenue	15,769	19,395	16,399	20,499	4%	6%
EBITDA	1,813	2,424	1,886	2,562	4%	6%
Adj. PAT	1,015	1,488	1,069	1,591	5%	7%

Financials and valuations

Consolidated - Income Statement

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	4,571	6,280	7,205	8,320	11,919	15,196	12,615	16,399	20,499
Change (%)	-4.9	37.4	14.7	15.5	43.2	27.5	-17.0	30.0	25.0
RM Cost	3,649	4,953	5,440	6,452	9,200	11,082	7,522	10,168	12,914
Employees Cost	441	469	517	647	1,174	1,862	2,251	2,542	2,767
Other Expenses	344	399	409	344	435	800	1,539	1,804	2,255
Total Expenditure	4,434	5,821	6,365	7,442	10,809	13,745	11,312	14,513	17,937
% of Sales	97.0	92.7	88.3	89.4	90.7	90.4	89.7	88.5	87.5
EBITDA	137	460	840	878	1,110	1,452	1,302	1,886	2,562
Margin (%)	3.0	7.3	11.7	10.6	9.3	9.6	10.3	11.5	12.5
Depreciation	106	185	193	194	223	341	428	457	476
EBIT	31	275	647	684	887	1,111	875	1,429	2,087
Int. and Finance Charges	182	208	220	315	344	375	272	200	180
Other Income	78	89	79	63	278	262	167	200	220
PBT bef. EO Exp.	-72	156	507	432	821	997	770	1,429	2,127
EO Items	0	0	0	0	0	80	-162	0	0
PBT after EO Exp.	-72	156	507	432	821	917	932	1,429	2,127
Total Tax	-5	38	109	114	209	236	199	360	535
Tax Rate (%)	7.2	24.2	21.6	26.5	25.5	25.8	21.3	25.2	25.2
Minority Interest	0	0	0	0	0	0	0	0	0
Reported PAT	-67	118	398	317	612	681	733	1,069	1,591
Adjusted PAT	-67	118	398	317	612	739	571	1,069	1,591
Change (%)	760.3	-276.3	236.0	-20.2	92.9	20.8	-22.7	87.2	48.9
Margin (%)	-1.5	1.9	5.5	3.8	5.1	4.9	4.5	6.5	7.8

Consolidated - Balance Sheet

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	14	14	14	529	793	793	794	794	794
Total Reserves	243	363	757	1,450	8,297	8,701	9,327	10,397	11,988
Net Worth	257	377	771	1,979	9,090	9,494	10,121	11,190	12,782
Total Loans	3,080	2,790	3,369	3,145	1,336	2,438	1,061	561	61
Deferred Tax Liabilities	-62	-51	-39	0	0	0	0	0	0
Capital Employed	3,275	3,116	4,101	5,123	10,425	11,932	11,182	11,751	12,843
Gross Block	1,705	2,650	2,668	2,750	3,285	4,513	4,961	5,203	5,612
Less: Accum. Deprn.	674	824	977	1,171	1,394	1,734	2,162	2,619	3,095
Net Fixed Assets	1,032	1,826	1,692	1,579	1,891	2,779	2,799	2,584	2,516
Goodwill on Consolidation	30	30	30	30	30	681	749	749	749
Capital WIP	774	23	34	13	10	56	21	229	271
Total Investments	3	3	3	895	662	309	302	302	302
Curr. Assets, Loans&Adv.	4,034	4,517	5,971	8,529	13,440	13,115	12,550	14,232	16,826
Inventory	2,226	1,555	2,696	4,251	4,642	5,713	6,473	4,485	5,484
Account Receivables	546	2,264	1,523	1,617	2,259	3,474	3,073	4,256	5,320
Cash and Bank Balance	661	342	1,218	1,676	5,366	2,878	1,258	3,674	3,751
Loans and Advances	601	357	534	985	1,173	1,050	1,746	1,817	2,272
Curr. Liability & Prov.	2,599	3,284	3,629	5,924	5,607	5,007	5,240	6,345	7,821
Account Payables	1,205	1,928	1,932	2,853	3,200	2,499	2,733	3,343	4,069
Other Current Liabilities	1,330	1,262	1,564	2,973	2,297	2,326	2,359	2,788	3,485
Provisions	64	93	134	98	110	182	147	214	268
Net Current Assets	1,435	1,233	2,342	2,605	7,832	8,107	7,311	7,887	9,005
Appl. of Funds	3,274	3,116	4,101	5,123	10,425	11,932	11,182	11,751	12,843

Financials and valuations

Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)									
EPS	-0.8	1.5	5.0	4.0	7.7	9.3	7.2	13.5	20.1
Cash EPS	0.5	3.8	7.4	6.4	10.5	13.6	12.6	19.2	26.1
BV/Share	3.2	4.7	9.7	25.0	114.6	119.7	127.6	141.1	161.2
Valuation (x)									
P/E	-736.3	417.6	124.3	155.8	80.7	66.8	86.5	46.2	31.0
Cash P/E	1,276.7	163.1	83.7	96.6	59.2	45.8	49.5	32.4	23.9
P/BV	192.2	131.2	64.1	25.0	5.4	5.2	4.9	4.4	3.9
EV/Sales	11.3	8.3	7.2	6.1	3.8	3.2	3.9	2.8	2.2
EV/EBITDA	377.7	112.9	61.4	58.0	40.9	33.7	37.7	24.5	17.8
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	-8.4	0.9	5.2	5.8	-13.2	-14.2	1.2	36.7	6.8
Return Ratios (%)									
RoE	-22.1	37.3	69.3	23.1	11.1	8.0	5.8	10.0	13.3
RoCE	3.8	8.5	15.6	11.9	11.2	9.1	7.1	10.6	14.0
RoIC	1.9	9.1	18.1	18.7	19.1	12.6	7.5	12.5	19.4
Working Capital Ratios									
Fixed Asset Turnover (x)	2.7	2.4	2.7	3.0	3.6	3.4	2.5	3.2	3.7
Asset Turnover (x)	1.4	2.0	1.8	1.6	1.1	1.3	1.1	1.4	1.6
Inventory (Days)	201	139	143	196	176	171	296	161	155
Debtor (Days)	70	82	96	69	59	69	95	95	95
Creditor (Days)	108	115	130	135	120	94	127	120	115
Leverage Ratio (x)									
Current Ratio	1.6	1.4	1.6	1.4	2.4	2.6	2.4	2.2	2.2
Interest Cover Ratio	0.2	1.3	2.9	2.2	2.6	3.0	3.2	7.1	11.6
Net Debt/Equity	9.4	6.5	2.8	0.7	-0.4	0.0	0.0	-0.3	-0.3

Consolidated - Cash Flow Statement

(INRm)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	-67	118	398	317	821	917	932	1,429	2,127
Depreciation	106	185	193	194	223	341	428	457	476
Interest & Finance Charges	133	171	175	267	344	375	272	0	-40
Direct Taxes Paid	3	1	-62	-168	-195	-257	-224	-360	-535
(Inc)/Dec in WC	-105	-200	-329	-229	-1,676	-1,976	-491	1,840	-1,041
CF from Operations	69	275	375	381	-483	-600	916	3,366	986
Others	93	74	111	158	-222	-24	-377	0	0
CF from Operating incl EO	163	349	486	539	-705	-624	539	3,366	986
(Inc)/Dec in FA	-830	-274	-77	-76	-338	-500	-447	-450	-450
Free Cash Flow	-667	75	409	463	-1,043	-1,124	92	2,916	536
(Pur)/Sale of Investments	-3	0	0	-892	0	0	0	0	0
Others	-51	265	-247	-450	-3,940	1,767	2,083	200	220
CF from Investments	-884	-9	-324	-1,418	-4,277	1,267	1,636	-250	-230
Issue of Shares	0	0	0	889	7,000	0	1	0	0
Inc/(Dec) in Debt	905	-336	534	-4	-1,647	323	-1,512	-500	-500
Interest Paid	-183	-92	-73	-145	-192	-644	-235	-200	-180
Dividend Paid	0	0	0	0	0	0	0	0	0
Others	0	-232	0	-19	-371	-266	-129	0	0
CF from Fin. Activity	723	-660	461	721	4,790	-587	-1,876	-700	-680
Inc/Dec of Cash	2	-320	622	-158	-193	55	299	2,416	76
Opening Balance	596	662	342	1,218	1,676	5,366	2,878	1,258	3,674
Other cash & cash equivalent	64	0	254	616	3,883	-2,544	-1,919	0	0
Closing Balance	662	342	1,218	1,676	5,366	2,878	1,258	3,674	3,751

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	> - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

MOFSL, its associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- received any compensation/other benefits from the subject company of this report
- managed or co-managed public offering of securities from subject company of this research report,
- received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

- MOFSL and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

- a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
- (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement	Cyient DLM
Analyst ownership of the stock	No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration

provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act of Singapore. Accordingly, if a Singapore person is not, or ceases to be, such an investor, they must immediately discontinue any use of this Report and inform MOCMSPL.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.